News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Controversial Trial Discovers No Benefit For Expensive The Medicines Company (MDCO) Drug


7/8/2014 6:30:00 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Although there is broad consensus in the medical community that immediate stenting (primary PCI) is the best treatment for heart attack patients when it can be delivered promptly, there is no agreement about the best accompanying drug regimen, which usually entails a combination of antiplatelet and antithrombotic drugs. The role of one antithrombotic, bivalirudin (Angiomax, The Medicines Company MDCO -2.7%) has been particularly uncertain because it is far more expensive than its alternative, unfractionated heparin.

Hey, check out all the research scientist jobs. Post your resume today!

Read at Forbes


comments powered by Disqus
Forbes
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES